IEHP Medi-Cal Formulary Change for Lantus

Dear IEHP Provider,

As of August 2018, the IEHP Pharmacy and Therapeutics Subcommittee approved the following Medi-Cal Formulary changes:

- Effective December 1, 2018 Lantus (insulin glargine) will be removed from the Medi-Cal Formulary. Our formulary agent will be Basaglar (insulin glargine).

- Members who have filled Lantus within 180 days prior to December 1, 2018 will be allowed a transitional fill period to consult with their providers on therapy options. This transitional fill period will end February 1, 2019.

- Beginning February 1, 2019, all Members must be transitioned to formulary Basaglar (insulin glargine). All Lantus treatments will require a Prior Authorization review.

The American Diabetes Association (ADA) recommends long acting basal insulin analogs over NPH insulin to reduce the risk of symptomatic and nocturnal hypoglycemia. Currently, long acting basal insulin options available on IEHP Medi-Cal Formulary are Lantus and Basaglar. Between these, the ADA does not prefer one agent over another. A head-to-head comparison of Basaglar and Lantus published in the Diabetes Therapy Journal demonstrated that both agents are equivalent in clinical efficacy and side effects.

IEHP understands that this transition can be difficult for our Providers and Members. We ask you to evaluate the risk and patient specific factors and discuss appropriate treatment options.

If you have any additional questions, please feel free to contact us at (909) 890-2049 between 8:00 AM -5:00 PM Monday through Friday. Thank you for your attention to this matter.

Sincerely,
IEHP Pharmaceutical Services